Table 1.
Patients’ baseline characteristics
| Characteristic | AD‐1021 | SOLO 1 | CHRONOS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo qw (n = 8) | Dupilumab 300 mg q2w (n = 10) | Dupilumab 300 mg qw (n = 9) | Placebo qw (n = 35) | Dupilumab 300 mg q2w (n = 36) | Dupilumab 300 mg qw (n = 35) | Placebo qw + TCS (n = 54) | Dupilumab 300 mg q2w + TCS (n = 16) | Dupilumab 300 mg qw + TCS (n = 47) | |
| Age (years) | 34 (26–59) | 38 (30–57) | 37 (21–43) | 42 (18–58) | 41 (20–59) | 37 (18–56) | 35 (19–67) | 38 (20–67) | 32 (19–56) |
| Male, n (%) | 6 (75) | 8 (80) | 7 (78) | 26 (74) | 27 (75) | 24 (69) | 36 (67) | 9 (56) | 32 (68) |
| BMI (kg m−2) | 21·4 (17·7–26·4) | 25·0 (20·7–30·5) | 22·4 (18·9–31·2) | 22·8 (17·0–44·0) | 22·8 (17·0–49·0) | 22·8 (17·0–36·0) | 22·4 (17·0–30·0) | 21·8 (19·0–33·0) | 23·2 (17·0–33·0) |
| AD duration (years) | 27 (18–40) | 32 (3–41) | 34 (18–39) | 33 (8–57) | 27 (15–58) | 31 (6–51) | 30 (4–47) | 30 (14–48) | 26 (8–53) |
| BSA affected (%) | 57 (35–88) | 76 (27–99) | 59 (21–88) | 74 (37–100) | 70 (34–100) | 71 (36–95) | 68 (33–100) | 62 (40–100) | 63 (28–97) |
| EASI score (0–72) | 33 (20–67) | 41 (19–56) | 33 (17–54) | 40 (17–72) | 37 (17–70) | 36 (17–64) | 36 (17–70) | 33 (19–61) | 37 (17–70) |
| Peak weekly averaged pruritus NRS (0–10) | 6 (4–9) | 6 (3–10) | 6 (4–9) | 8 (4–9) | 7 (0–10) | 7 (1–10) | 8 (3–10) | 7 (4–9) | 7 (2–10) |
| Total SCORAD (0–103) | 61 (36–97) | 74 (42–95) | 65 (48–77) | 72 (38–101) | 69 (43–99) | 68 (43–92) | 64 (46–101) | 73 (47–90) | 67 (41–95) |
| IGA 4 (severe), n (%) | 4 (50) | 4 (40) | 4 (44) | 24 (69) | 24 (67) | 23 (66) | 31 (57) | 8 (50) | 26 (55) |
| POEM score (0–28) | 21 (10–26) | 19 (6–28) | 17 (10–28) | 19 (4–28) | 20 (1–28) | 22 (2–28) | 20 (8–28) | 20 (4–25) | 19 (6–28) |
| DLQI score (0–30) | 12 (9–19) | 12 (1–26) | 6 (5–23) | 11 (2–27) | 11 (0–27) | 11 (1–26) | 11 (1–30) | 10 (3–24) | 10 (2–27) |
Values are the median (range) unless otherwise specified. AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure; qw, weekly; q2w, every 2 weeks; SCORAD, Scoring Atopic Dermatitis; TCS, topical corticosteroids.